A previous trial evaluated the treatment response of patients with non-small cell lung cancer to anti-PD-1 antibodies (nivolumab and pembrolizumab) after the failure of anti-PD-L1 antibodies (atezolizumab and durvalumab) [10]. Here, PDCD1 is linked to non-small cell lung carcinoma.